combined oxidative phosphorylation deficiency 39

ORPHA: 565624

Overview

human disease

Available Treatments (0)

No treatments linked yet

Clinical trials or compassionate use may be available — consult a specialist.

Clinical Presentation

Signs and symptoms associated with combined oxidative phosphorylation deficiency 39, sourced from HPO and Orphanet clinical annotations.

Optic disc pallorDelayed speech and language developmentReduced eye contactScoliosisMuscle spasmBabinski signInvoluntary movementsCongenital foot contracturesLateral ventricle dilatationAtrophy/Degeneration affecting the brainstemCorpus callosum atrophyAnkle clonusNasogastric tube feeding in infancyProminent calcaneusTip-toe gaitLeg dystoniaAbnormal corpus callosum morphologyAbnormal cerebellum morphologyCerebellar hypoplasiaAbsent speechBradycardiaPoor head controlIncreased CSF lactateAbnormal cerebral white matter morphologyLoss of ambulationDeep white matter hypodensitiesNo social interactionFeeding difficulties in infancyAxial hypotoniaSevere global developmental delayAbnormal circulating enzyme concentration or activityHyperintensity of cerebral white matter on MRICryptorchidismOpen mouthMicrocephalyDecreased nerve conduction velocitySeizureDysarthriaMuscle weaknessHyperreflexiaIntrauterine growth retardationNeonatal hypoglycemiaVomitingMyopathic faciesCerebral atrophyLower limb spasticityHypoplasia of the corpus callosumIncreased circulating lactate concentrationDroolingEEG abnormalityLimb hypertoniaHypsarrhythmia

Classification & Codes

Orphanet Code

ORPHA:565624
combined oxidative phosphorylation deficiency 39
OrphanetORPHA:565624
Treatments0 drug(s)
Symptoms on record52 signs
Statuspublished
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO
combined oxidative phosphorylation deficiency 39 | OrphanDrug